Literature DB >> 10478664

Use of keratin 35betaE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasia-ductal type--benign and malignant intraductal proliferations.

F Moinfar1, Y G Man, R A Lininger, C Bodian, F A Tavassoli.   

Abstract

A variety of studies have investigated the role of low molecular weight (LMW) and high molecular weight (HMW) cytokeratin (CK) expression in the normal breast and invasive breast carcinomas. A few studies with small numbers of cases have addressed this issue in intraductal proliferations of the breast. This study investigates the expression of these CKs in a large series of ductal intraepithelial neoplasias of the breast. We examined 150 ductal carcinomas in situ (DCIS), 35 cases of intraductal hyperplasia (IDH), and 15 cases of atypical intraductal hyperplasia (AIDH). Immunohistochemistry was performed using monoclonal antibodies against CK-34betaE12 (HMW CK), CK-8, and CK-19 (LMW CK) on formalin-fixed, paraffin-embedded tissue. The intensity (0, +1, +2, +3) and percentage of positive intraductal cells (0-100%) were multiplied to obtain a score from 0 to 300. The immunoprofiles of IDH, AIDH, and DCIS were categorized into four groups showing negative or low (0-60), moderate (61-100), high (101-200), and very high (201-300) scores. All cases of IDH showed an intensely positive reaction (high to very high scores) for CK-34betaE12. In contrast, 90% of the DCIS showed a negative or only focal and weak reaction (negative or low score) for this antigen. The remaining 10% of DCIS showed a positive immunoreaction for CK-34betaE12 with moderate to high scores. All cases of florid IDH and 96% of cases of DCIS expressed CK-8 intensely with high to very high scores. Although CK-19 was strongly expressed in 97% of cases of IDH (high to very high scores), a very high score was also found in 80% of cases of DCIS that were positive for CK-19. Of the 15 AIDHs, 80% had a negative or only focal reaction (negative or low score) for CK-34betaE12 and the remaining 20% had a moderate to high score for this antigen. Although CK-8 was strongly positive in 87% of cases of AIDH (high to very high scores), only 53.5% of AIDHs showed intense positivity for CK-19. The present study clearly shows that the immunoprofile of IDH is different from DCIS as far as HMW CK is concerned. Although florid IDH is characterized by a diffuse and intense immunoreaction for HMW CK, the lack of or only weak positivity for HMW CK (CK-34betaE12) is, in most cases, a hallmark of ductal carcinoma in situ. The immunoprofile of AIDH is very similar to that of DCIS. The expression of CK-8 and CK-19 is not useful in separating the various categories of ductal intraepithelial proliferations of the breast. We recommend the use of CK-34betaE12 as an adjunct in the diagnosis of a variety of problematic intraductal proliferations of the breast.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10478664     DOI: 10.1097/00000478-199909000-00007

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  12 in total

Review 1.  [Diagnostics of benign ductal epithelial cell proliferation of the breast in biopsy material].

Authors:  H-P Sinn; C Flechtenmacher; S Aulmann
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

2.  Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In Situ.

Authors:  Gary Tozbikian; Edi Brogi; Christina E Vallejo; Dilip Giri; Melissa Murray; Jeffrey Catalano; Cristina Olcese; Kimberly J Van Zee; Hannah Yong Wen
Journal:  Int J Surg Pathol       Date:  2016-08-04       Impact factor: 1.271

3.  E-cadherin and cytokeratin subtype profiling in effusion cytology.

Authors:  Joungho Han; Mi-Kyung Kim; Seok-Jin Nam; Jung-Hyun Yang
Journal:  J Korean Med Sci       Date:  2004-12       Impact factor: 2.153

4.  Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody.

Authors:  Magali Lacroix-Triki; Eliane Mery; Jean-Jacques Voigt; Luc Istier; Philippe Rochaix
Journal:  Virchows Arch       Date:  2003-04-24       Impact factor: 4.064

Review 5.  Clear cell carcinoma of the breast with solid papillary pattern: a case report with immunohistochemical profile.

Authors:  Y Gürbüz; S K Ozkara
Journal:  J Clin Pathol       Date:  2003-07       Impact factor: 3.411

6.  Cytokeratin immunoreactivity in lobular intraepithelial neoplasia.

Authors:  Gary L Bratthauer; Markku Miettinen; Fattaneh A Tavassoli
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

Review 7.  New trends of immunohistochemistry for making differential diagnosis of breast lesions.

Authors:  Takuya Moriya; Atsuko Kasajima; Kazuyuki Ishida; Yoshiyuki Kariya; Jun-Ichi Akahira; Mareyuki Endoh; Mika Watanabe; Hironobu Sasano
Journal:  Med Mol Morphol       Date:  2006-03       Impact factor: 2.070

8.  Flat DIN 1 (flat epithelial atypia) on core needle biopsy: 63 cases identified retrospectively among 1,751 core biopsies performed over an 8-year period (1992-1999).

Authors:  Maritza Martel; Patricia Barron-Rodriguez; Idris Tolgay Ocal; Jorge Dotto; Fattaneh A Tavassoli
Journal:  Virchows Arch       Date:  2007-09-05       Impact factor: 4.535

Review 9.  Precursors and preinvasive lesions of the breast: the role of molecular prognostic markers in the diagnostic and therapeutic dilemma.

Authors:  Flora Zagouri; Theodoros N Sergentanis; George C Zografos
Journal:  World J Surg Oncol       Date:  2007-05-31       Impact factor: 2.754

10.  Cell clusters overlying focally disrupted mammary myoepithelial cell layers and adjacent cells within the same duct display different immunohistochemical and genetic features: implications for tumor progression and invasion.

Authors:  Yan-gao Man; Lisa Tai; Ross Barner; Russell Vang; Jeffrey S Saenger; Kris M Shekitka; Gary L Bratthauer; Darren T Wheeler; Chang Y Liang; Tuyethoa N Vinh; Brian L Strauss
Journal:  Breast Cancer Res       Date:  2003-10-03       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.